Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01732445 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01732445: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01732445 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01732445, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
Interventions
- OTHER questionnaire administration
- OTHER quality-of-life assessment
- DRUG ruxolitinib phosphate
- DRUG danazol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01732445
The ClinicalTrials.gov registry entry for NCT01732445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which questionnaire administration is the first listed.
NCT01732445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01732445 about?
NCT01732445 is a clinical study titled "Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis". This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
What is the current status of trial NCT01732445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2013-04. Estimated completion is 2017-08-10.
What interventions are being tested in trial NCT01732445?
The interventions under investigation include: questionnaire administration (OTHER), quality-of-life assessment (OTHER), ruxolitinib phosphate (DRUG), danazol (DRUG).
Who is sponsoring clinical trial NCT01732445?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.